New MedPredict Report Highlights Recent Advances In Management Of Malignant Hematology

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Blood / Hematology
Article Date: 16 Jan 2010 - 1:00 PDT

email to a friend   printer friendly   opinions  

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematologists from North America immediately following the American Society of Hematology (ASH) annual meeting.

This report, entitled "Thought Leader Insight & Analysis Malignant Hematology," includes analysis of new research in Multiple Myeloma, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Lymphoma, and Chronic Myelogenous Leukemia.

"This report reflects on and analyzes the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key focus of the report is Multiple Myeloma (MM), which is being transformed into a chronic, but still life threatening disease. The most exciting advances presented at ASH included both identifying the most effective combinations for induction therapy, and in establishing a role and practice standard for maintenance therapy in MM."

According to one MM Thought Leader interviewed for this report: "I think the message was very positive in regards that maintenance matters, choice of induction strategy matters with less toxicity being important, and staying on treatment of some form or another is very critical."

The expert panel also discusses novel compounds in development for various hematologic malignancies, and the hurdles they will need to overcome to become viable options in this market.

Companies and partnerships mentioned in this report includes: Allos, Ambit, Amgen, Arno Therapeutics, Antisoma, Biogen Idec/Elan, Biotest/ImmunoGen, Bristol-Myers Squibb, Bristol-Myers Squibb/Facet, Celgene, Celgene/Gloucester, Cephalon, ChemGenex, Cyclacel, Eisai, Genmab, Genzyme, Genzyme/Anormed, Genzyme/Bayer HealthCare Pharmaceuticals, Geron/Merck, GlaxoSmithKline, GlaxoSmithKline/Genmab, ImmunoGen, Immunomedics/Nycomed, Incyte, Keryx, Merck, Milteni Biotec, Novartis, Novartis/Vernalis, OXiGENE, PDL Biopharma, Proteolix/Onyx, Rigel, Seattle Genetics, Syndax, and Takeda/Millennium.

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

Source: MedPredict

• Additional
• References
• Citations